DUBLIN, IRELAND / ACCESSWIRE / November 7, 2023 / Nemysis is pleased to announce receipt of grant funding under the European Horizon program, to advance the development of its E40 glutenase to Market Authorization for the management of gluten intolerance (celiac disease) and sensitivity.
DUBLIN, IRELAND / ACCESSWIRE / October 17, 2023 / Nemysis is pleased to announce that the company was recently covered by a research note published by The Life Sciences Division Limited (TLSD), a boutique investment bank based in London, specialising in the life sciences sector.